QS-21 |
Catalog No.GC63377
One-Click Copy Product Info
|
QS-21은 면역 증폭 작용을 하는 사포닌으로, 효과적인 백신 부조제로 사용될 수 있다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 141256-04-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
QS-21은 면역 증폭 작용을 하는 사포닌으로, 효과적인 백신 부조제로 사용될 수 있다. QS-21은 덴드리트 세포와 도움 T 세포를 활성화하여 백신 면역 반응을 강화하고, 항체 생성과 세포 중재 면역 반응을 촉진한다[2]. QS-21은 NLRP3 인플라마소메의 활성화제로, 이어서 caspase-1에 의존하는 염증성 인자인 IL-1β와 IL-18을 방출시킨다[3].
체외 실험에서QS-21(2.5, 5, 25 μM)은 HUVEC 및 PBMC 세포에 24시간 처리하여 세포 활성을 현저하게 감소시켰으며, HUVEC 세포에서의 세포 독성 효과가 더욱 두드러졌다[4]. QS-21(0-50 μM)은 두 가지 인간 위암 세포 계열(SNU 1와 KATO III)과 정상 인간 세포 계열(GES-1)에 대해 24시간 처리하여, KATO III와 SNU 1 세포의 독성이 용량에 따라 달라지며, 각각의 IC50 값이 67μM과 13.6μM이었다. 하지만 GES-1 세포에 거의 세포 독성을 보이지 않았다[5].
체내 실험에서 QS-21 부조제로 제형화된 Aβ42으로 인공 면역화된 쥐에서 가장 높은 항체 티터가 생성되었으며, 그 다음은 CFA/IFA > 명연 > TMG[6] 순이다.
References:
[1] Marty-Roix R, Vladimer G I, Pouliot K, et al. Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants[J]. Journal of Biological Chemistry, 2016, 291(3): 1123-1136.
[2] Welsby I, Detienne S, N’Kuli F, et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21[J]. Frontiers in immunology, 2017, 7: 663.
[3] Lacaille-Dubois M A. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review[J]. Phytomedicine, 2019, 60: 152905.
[4] Campos-Estrada C, Riquelme B, Vergara M, et al. In vitro Notch-mediated adjuvant immunogenic potency is induced by combining QS-21 and MPL in a co-culture model of PBMC and HUVEC cells[J]. Toxicology in Vitro, 2020, 68: 104947.
[5] Guzmán L, Villalón K, Marchant M J, et al. In vitro evaluation and molecular docking of QS-21 and quillaic acid from Quillaja saponaria Molina as gastric cancer agents[J]. Scientific Reports, 2020, 10(1): 10534.
Cribbs D H, Ghochikyan A, Vasilevko V, et al. Adjuvant‐dependent modulation of Th1 and Th2 responses to immunization with β‐amyloid[J]. International immunology, 2003, 15(4): 505-514.
| Cas No. | 141256-04-4 | SDF | |
| Formula | C92H148O46 | M.Wt | 1990.13 |
| Solubility | DMSO : 100 mg/mL (50.25 mM; Need ultrasonic); H2O : 50 mg/mL (25.12 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 502.5 μL | 2.5124 mL | 5.0248 mL |
| 5 mM | 100.5 μL | 502.5 μL | 1.005 mL |
| 10 mM | 50.2 μL | 251.2 μL | 502.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)